Physician profile
Maya Atallah
NPI 1851186225
$532.74
in general payments reported to CMS, 2019-2025
10 companies · $533 in 2025
The $533 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $268.27 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $54.26 | 2025 | Kisunla, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $41.00 | 2025 | Rexulti |
| Exact Sciences Corporation | $30.30 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $28.27 | 2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $27.75 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $25.13 | 2025 | |
| Edwards Lifesciences Corporation | $22.60 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Paratek Pharmaceuticals, INC. | $20.53 | 2025 | Nuzyra |
| Astellas Pharma US INC | $14.63 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Atallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.